Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Importance: Evidence-based therapies to reduce atherosclerotic cardiovascular disease risk in adults with type 2 diabetes are underused in clinical practice. Objective: To assess the effect of a coordinated, multifaceted intervention of assessment, education, and feedback vs usual care on the proportion of adults with type 2 diabetes and atherosclerotic cardiovascular disease prescribed all 3 groups of recommended, evidence-based therapies (high-intensity statins, angiotensin-converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARBs], and sodium-glucose cotransporter 2 [SGLT2] inhibitors and/or glucagon-like peptide 1 receptor agonists [GLP-1RAs]). Design, Setting, and Participants: Cluster randomized clinical trial with 43 US cardiology clinics recruiting participants from July 2019 through May 2022 and follow-up through December 2022. The participants were adults with type 2 diabetes and atherosclerotic cardiovascular disease not already taking all 3 groups of evidence-based therapies. Interventions: Assessing local barriers, developing care pathways, coordinating care, educating clinicians, reporting data back to the clinics, and providing tools for participants (n = 459) vs usual care per practice guidelines (n = 590). Main Outcomes and Measures: The primary outcome was the proportion of participants prescribed all 3 groups of recommended therapies at 6 to 12 months after enrollment. The secondary outcomes included changes in atherosclerotic cardiovascular disease risk factors and a composite outcome of all-cause death or hospitalization for myocardial infarction, stroke, decompensated heart failure, or urgent revascularization (the trial was not powered to show these differences). Results: Of 1049 participants enrolled (459 at 20 intervention clinics and 590 at 23 usual care clinics), the median age was 70 years and there were 338 women (32.2%), 173 Black participants (16.5%), and 90 Hispanic participants (8.6%). At the last follow-up visit (12 months for 97.3% of participants), those in the intervention group were more likely to be prescribed all 3 therapies (173/457 [37.9%]) vs the usual care group (85/588 [14.5%]), which is a difference of 23.4% (adjusted odds ratio [OR], 4.38 [95% CI, 2.49 to 7.71]; P < .001) and were more likely to be prescribed each of the 3 therapies (change from baseline in high-intensity statins from 66.5% to 70.7% for intervention vs from 58.2% to 56.8% for usual care [adjusted OR, 1.73; 95% CI, 1.06-2.83]; ACEIs or ARBs: from 75.1% to 81.4% for intervention vs from 69.6% to 68.4% for usual care [adjusted OR, 1.82; 95% CI, 1.14-2.91]; SGLT2 inhibitors and/or GLP-1RAs: from 12.3% to 60.4% for intervention vs from 14.5% to 35.5% for usual care [adjusted OR, 3.11; 95% CI, 2.08-4.64]). The intervention was not associated with changes in atherosclerotic cardiovascular disease risk factors. The composite secondary outcome occurred in 23 of 457 participants (5%) in the intervention group vs 40 of 588 participants (6.8%) in the usual care group (adjusted hazard ratio, 0.79 [95% CI, 0.46 to 1.33]). Conclusions and Relevance: A coordinated, multifaceted intervention increased prescription of 3 groups of evidence-based therapies in adults with type 2 diabetes and atherosclerotic cardiovascular disease. Trial Registration: ClinicalTrials.gov Identifier: NCT03936660
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Self-citationJoseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M., Morris, P. B., Neumiller, J. J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.037 · Cited by 466
Self-citation10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
Self-citationNelson, A. J., O’Brien, E. C., Kaltenbach, L. A., Green, J. B., Lopes, R. D., Morse, C. G., Al-Khalidi, H. R., Aroda, V. R., Cavender, M. A., Gaynor, T., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.48030 · Cited by 78
Self-citation
Research works printed but not linked: 16
- Foulquier, 2014, Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis., J Hypertens, 32, 1334, 10.1097/HJH.0000000000000154 · DOI
- Nelson, 2021, Gaps in evidence-based therapy use in insured patients in the United States with type 2 diabetes mellitus and atherosclerotic cardiovascular disease., J Am Heart Assoc, 10, 10.1161/JAHA.120.016835 · DOI · Paper page
- Nelson, 2023, Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE)—diabetes: rationale and design., Am Heart J, 256, 2, 10.1016/j.ahj.2022.10.079 · DOI
- Mallinckrodt, 2004, Choice of the primary analysis in longitudinal clinical trials., Pharm Stat, 3, 161, 10.1002/(ISSN)1539-1612 · DOI
- Kaplan, 1958, Nonparametric estimation from incomplete observations., J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 · DOI · Paper page
- Austin, 2017, A tutorial on multilevel survival analysis: methods, models and applications., Int Stat Rev, 85, 185, 10.1111/insr.v85.2 · doi:10.1111/insr.v85.2
- Vinereanu, 2017, A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial., Lancet, 390, 1737, 10.1016/S0140-6736(17)32165-7 · DOI · Paper page
- Chan, 2017, ACC/AHA special report: clinical practice guideline implementation strategies: a summary of systematic reviews by the NHLBI Implementation Science Work Group: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines., Circulation, 135, e122, 10.1161/CIR.0000000000000481 · DOI · Paper page
- Wang, 2019, Effect of medication co-payment vouchers on P2Y12 inhibitor use and major adverse cardiovascular events among patients with myocardial infarction: the ARTEMIS randomized clinical trial., JAMA, 321, 44, 10.1001/jama.2018.19791 · DOI
- Choudhry, 2011, Full coverage for preventive medications after myocardial infarction., N Engl J Med, 365, 2088, 10.1056/NEJMsa1107913 · DOI · Paper page
- Adusumalli, 2023, Effect of nudges to clinicians, patients, or both to increase statin prescribing: a cluster randomized clinical trial., JAMA Cardiol, 8, 23, 10.1001/jamacardio.2022.4373 · DOI
- Ghazi, 2022, Electronic alerts to improve heart failure therapy in outpatient practice: a cluster randomized trial., J Am Coll Cardiol, 79, 2203, 10.1016/j.jacc.2022.03.338 · DOI · Paper page
- Allen, 2021, An electronically delivered patient-activation tool for intensification of medications for chronic heart failure with reduced ejection fraction: the EPIC-HF trial., Circulation, 143, 427, 10.1161/CIRCULATIONAHA.120.051863 · DOI · Paper page
- Blood, 2023, Results of a remotely delivered hypertension and lipid program in more than 10?000 patients across a diverse health care network., JAMA Cardiol, 8, 12, 10.1001/jamacardio.2022.4018 · DOI · Paper page
- Thomas, 2021, Cardiometabolic center of excellence: a novel care delivery model for secondary prevention of cardiovascular disease in type 2 diabetes., Circ Cardiovasc Qual Outcomes, 14, 10.1161/CIRCOUTCOMES.120.007682 · DOI · Paper page
- Neeland, 2022, Lessons learned from a patient-centered, team-based intervention for patients with type 2 diabetes at high cardiovascular risk: year 1 results from the CINEMA program., J Am Heart Assoc, 11, 10.1161/JAHA.120.024482 · DOI
Cited by
Ndumele, C. E., Neeland, I. J., Tuttle, K. R., Chow, S. L., Mathew, R. O., Khan, S. S., Coresh, J., Baker-Smith, C. M., Carnethon, M. R., Després, J.-P., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001186 · Cited by 1,405
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Self-citationSterling, M. R., Ferranti, E. P., Green, B. B., Moise, N., Foraker, R., Nam, S., Juraschek, S. P., Anderson, C. A. M., St. Laurent, P., Sussman, J., et al. (2024) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000134 · Cited by 29
Jack, G. A., Avenatti, E., Kashyap, S. R., & Sadhu, A. R. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf301 · Cited by 9
Metadata
- Authors
- Pagidipati, N. J., Nelson, A. J., Kaltenbach, L. A., Leyva, M., McGuire, D. K., Pop-Busui, R., Cavender, M. A., Aroda, V. R., Magwire, M. L., Richardson, C. R., Lingvay, I., Kirk, J. K., Al-Khalidi, H. R., Webb, L., Gaynor, T., Pak, J., Senyucel, C., Lopes, R. D., Green, J. B., Granger, C. B., COORDINATE–Diabetes Site Investigators, Kumar, P., Mahal, S., Javier, J., Purdy, D., Ahmed, S., Schmidt, D., Sharma, S., Salacata, A., Covalesky, J., Paraschos, A., Cohan, K., Walia, J., Ranadive, N., Flood, R., Friedman, K., Bayron, C., Weston, P., Adler, A., Viswanath, D., Calhoun, L., Khandelwal, A., Cohen, M., Zarich, S., Gianos, E., Korabathina, R., Mehta, R., Hochrein, J., Arora, V., Cruz, J., Pacheco-Coronado, R., Kelly, J., Garg, R., Ogunniyi, M., Weinberg, M., Davuluri, A., Danciu, S., Almousalli, O., Bellamkonda, P., Nwakile, C., Sokolowicz, J., Martin, E., Kerut, K., Pandey, A., Vijay, N., Bui, H., Khan, W., Morrow, M., Prashad, R., & Bruemmer, D.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2023-04-18
- Volume
- 329
- Issue
- 15
- Pages
- 1261
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4323293774
- Cited by
- 105
- References
- 10
- FWCI
- 17.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2023.2854
- The paper
- Pagidipati, N. J., Nelson, A. J., Kaltenbach, L. A., Leyva, M., McGuire, D. K., Pop-Busui, R., Cavender, M. A., Aroda, V. R., Magwire, M. L., Richardson, C. R., Lingvay, I., Kirk, J. K., Al-Khalidi, H. R., Webb, L., Gaynor, T., Pak, J., Senyucel, C., Lopes, R. D., Green, J. B., . . . Bruemmer, D. (2023). Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2023.2854
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.